Literature DB >> 22222307

Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis.

Shuuichi Mori1, Shigeru Yamada, Sachiho Kubo, Jie Chen, Seiji Matsuda, Masachika Shudou, Naoki Maruyama, Kazuhiro Shigemoto.   

Abstract

Muscle-specific kinase (MuSK), a receptor tyrosine kinase, is required for the formation and maintenance of neuromuscular junctions (NMJs). Although autoantibodies against MuSK have been demonstrated to cause myasthenia gravis (MG), the underlying pathogenic mechanism remains unclear because a major subclass of these antibodies is functionally monovalent. We investigated the pathogenic role of MuSK antibodies in the onset of MG in vivo and in vitro. Ultrastructural visualization of NMJs in paretic rabbits with MuSK antibodies indicated that postsynaptic membranes were preserved, despite a significant loss of complexity in the convoluted synaptic folds. In addition, an in vitro assay indicated that both divalent and monovalent antibodies from paretic rabbits could interfere with agrin-induced acetylcholine receptor (AChR) clustering in cultured myotubes. Furthermore, in the absence of agrin, divalent antibodies induced MuSK phosphorylation and accelerated downregulation of Dok-7, an essential intracellular MuSK binding protein, while monovalent antibodies inhibited agrin-induced phosphorylation of MuSK, thus demonstrating distinct molecular mechanisms underlying the MuSK dysfunction induced by these two types of antibodies. Taken together, these findings suggest that complement activation is not necessary for the MG onset and that both divalent and monovalent antibodies may cause MG in vivo by inducing MuSK dysfunction. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222307     DOI: 10.1016/j.jneuroim.2011.12.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

1.  Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.

Authors:  Nazanin Ghazanfari; Marco Morsch; Stephen W Reddel; Simon X Liang; William D Phillips
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

2.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 3.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

4.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Authors:  Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

5.  Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.

Authors:  Marco Morsch; Stephen W Reddel; Nazanin Ghazanfari; Klaus V Toyka; William D Phillips
Journal:  J Physiol       Date:  2013-02-25       Impact factor: 5.182

Review 6.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

7.  Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.

Authors:  Kenji Otsuka; Mikako Ito; Bisei Ohkawara; Akio Masuda; Yu Kawakami; Ko Sahashi; Hiroshi Nishida; Naoki Mabuchi; Akemi Takano; Andrew G Engel; Kinji Ohno
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

8.  Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.

Authors:  Nazanin Ghazanfari; Marco Morsch; Nigel Tse; Stephen W Reddel; William D Phillips
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

Review 9.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

10.  MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.

Authors:  Inga Koneczny; Judith Cossins; Patrick Waters; David Beeson; Angela Vincent
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.